Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion

Join Dr. Moul and Dr. Morris, 2 tenured researchers and clinicians in the field of prostate cancer, as they discuss apalutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer. Through discussion of patient case studies, this webinar will highlight key data from the Phase 3 TITAN study and review the efficacy and safety data of apalutamide with ADT. Dr.'s Moul and Morris will also delve into subpopulation analyses and exploratory prostate-specific antigen kinetics from the TITAN study.

Judd Moul, MD, FACS

James H. Semans, MD Distinguished Professor of Urologic Surgery, in the School of Medicine at Duke University School of Medicine, Durham, NC Received the Distinguished Contribution Award, American Urologic Association, in 2023 Author of over 500 peer reviewed publications

David Morris, MD, FACS

President and Co-Director of the Advanced Therapeutics Center at Urology Associates, P.C, Nashville, TN Actively assists in the coordination of Advanced Therapeutics Center for prostate cancer therapies and their clinical research trials Authored and co-authored multiple scientific papers and has presented research findings at regional and national meetings

AUANWW: Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion Recording

Duration

00:34:47

Event Details